Diagnostics Accelerator Updates

• Research Update

  May 28, 2020

  First-of-its-Kind Study Shows the Substantial Economic Burden of Early Stage Alzheimer’s on Patients, Caregivers and Society

  A first-of-its kind study shows a substantial economic impact of early stages of Alzheimer’s on patients and families—$2,816 per month in direct medical care and informal caregiver costs for those with mild cognitive impairment (MCI) and $4,243 per month for patients who have progressed to mild dementia.

• New Investments

  December 4, 2019

  Alzheimer’s Drug Discovery Foundation’s Diagnostics Accelerator Announces Second Round of Awards

  $50 million global research initiative, funded by Leonard A. Lauder, Bill Gates, Jeff and MacKenzie Bezos, among other leading philanthropists, targets resources to speed up development of blood, digital and other biomarkers for early detection of Alzheimer's disease and related dementias.

• Events

  May 31, 2019

  Thirteenth Connoisseur's Dinner Recognizes Core Funders of Its Diagnostics Accelerator

  The ADDF celebrated the one-year anniversary of the Diagnostics Accelerator initiative and its core funders at the ADDF's annual gala.

• Initiatives

  May 30, 2019

  Alzheimer’s Drug Discovery Foundation Announces the First Award Recipients of its Diagnostics Accelerator Program

  The first four awards from the first request for proposals total up to approximately $3.5 million.

• Initiatives

  January 3, 2019

  The Alzheimer’s Drug Discovery Foundation’s Diagnostics Accelerator Initiative Expands Its Focus on Frontotemporal Degeneration

  The ADDF's Diagnostics Accelerator is matching a $2.5 million research investment from The Association for Frontotemporal Degeneration to invest in biomarkers for frontotemporal dementia.

• Research Update

  February 5, 2013

  Medicare Panel’s Failure to Recommend Payment for New Alzheimer’s Diagnostic Brain Imaging Scans

  Howard Fillit, MD and George Vradenburg of USAgainstAlzheimer's issued a joint statement, responding to MEDCAC's opinion to not support Medicare reimbursement for PET amyloid imaging scans.

• Research Update

  April 6, 2012

  ADDF’s Seed Funding Leads to FDA Approval of Amyvid™, First Diagnostic Test for Alzheimer’s Disease

  The FDA has approved Amyvid™, the first diagnostic test for Alzheimer's disease, for which the ADDF provided critical seed funding.

View More